×

Angiotensin II Type 1 Receptor Blockers

  • Michel Burnier
  • From the Division of Hypertension and Vascular Medicine, CHUV, Lausanne, Switzerland.
Originally publishedCirculation. 2001;103:904–912
First page image

Footnotes

Correspondence to Prof M. Burnier, Division of Hypertension and Vascular Medicine, Hôpital Nestlé, Av P. Decker, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne/Switzerland. E-mail

References

  • 1 Gavras H, Brown JJ, Lever AF, et al. Acute renal failure, tubular necrosis and myocardial infarction induced in the rabbit by intravenous angiotensin II. Lancet.1971;2:19–22.CrossrefMedline
  • 2 Brunner HR, Laragh JR, Baer L, et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med.1972;286:441–449.CrossrefMedline
  • 3 Brunner HR, Kirsman DJ, Sealey JE, et al. Hypertension of renal origin: evidence for two different mechanisms. Science.1971;174:1344–1346.CrossrefMedline
  • 4 Gavras H, Brunner HR, Vaughan ED Jr, et al. Angiotensin-sodium interaction in blood pressure maintenance of renal hypertensive and normotensive rats. Science.1973;180:1369–1372.CrossrefMedline
  • 5 Brunner HR, Gavras H, Laragh JH, et al. Angiotensin-II blockade in man by Sar1-Ala8-angiotensin II for understanding and treatment of high blood pressure. Lancet.1973;2:1045–1048.CrossrefMedline
  • 6 Brunner HR, Gavras H, Laragh JH, et al. Hypertension in man, exposure of the renin and sodium components using angiotensin II blockade. Circ Res. 1974;34(suppl 1):35–43.
  • 7 Gavras H, Ribeiro AB, Gavras I, et al. Reciprocal relation between renin dependency and sodium dependency in essential hypertension. N Engl J Med.1976;295:1278–1283.CrossrefMedline
  • 8 Gavras H, Flessas A, Ryan TJ, et al. Angiotensin II inhibition: treatment of congestive cardiac failure in a high-renin hypertension. JAMA.1977;238:880–892.CrossrefMedline
  • 9 Turini GA, Brunner HR, Ferguson RK, et al. Congestive heart failure in normotensive man: hemodynamics, renin and angiotensin II blockade. Br Heart J.1978;40:1134–1142.CrossrefMedline
  • 10 Ferguson RK, Turini GA, Brunner HR, et al. A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet.1977;1:775–778.CrossrefMedline
  • 11 Gavras H, Brunner HR, Turini GA, et al. Antihypertensive effect of the oral angiotensin converting enzyme inhibitor SQ 14225 in man. N Engl J Med.1978;298:991–995.CrossrefMedline
  • 12 Brunner HR, Waeber B, Wauters JP, et al. Inappropriate renin secretion in hypertension of chronic renal failure unmasked by captopril (SQ 14,225). Lancet.1978;2:704–707.CrossrefMedline
  • 13 Brunner HR, Gavras H, Waeber B, et al. Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann Int Med.1979;90:19–23.CrossrefMedline
  • 14 Turini GA, Brunner HR, Gribic M, et al. Improvement of chronic congestive heart failure by oral captopril. Lancet.1979;1:1213–1215.Medline
  • 15 Faxon DP, Creager MA, Halperin JL, et al. Central and peripheral hemodynamic effects of angiotensin inhibition in patients with refractory congestive heart failure. Circulation.1980;61:925–931.CrossrefMedline
  • 16 The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med.1987;316:1429–1435.CrossrefMedline
  • 17 Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med.1993;329:1456–1462.CrossrefMedline
  • 18 The Heart Outcomes Prevention Evaluation study investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Eng J Med.2000;342:145–153.CrossrefMedline
  • 19 Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev.1993;45:205–251.Medline
  • 20 Dzau VJ, Sasamura H, Hein L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J Hypertens. 1993;11(suppl 3):S13–S22.
  • 21 Urata K, Kinoshita A, Misono K, et al. Identification of a highly specific chymase as the major angiotensin-forming enzyme in the human heart. J Biol Chem.1990;265:22348–22382.Medline
  • 22 Linz W, Wiemer G, Gohlke P, et al. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev.1995;47:25–49.Medline
  • 23 Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angio-oedema. Lancet.1998;351:1693–1697.CrossrefMedline
  • 24 Bao G, Gohlke P, Qadri F, et al. Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril. Hypertension.1992;20:74–79.
  • 25 Danckwart L, Shimizu I, Bonner G, et al. Converting enzyme inhibition in kinin-deficient brown Norway rats. Hypertension.1990;16:429–435.
  • 26 Linz W, Scholkens BA. A specific B2 bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol.1992;105:771–772.CrossrefMedline
  • 27 Bouaziz H, Joulin Y, Safar M, et al. Effects of bradykinin B2 receptor antagonism on the hypotensive effects of ACE inhibition. Br J Pharmacol.1994;113:717–722.CrossrefMedline
  • 28 Gainer JV, Morrow JD, Loveland A et al. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med.1998;339:1285–1292.CrossrefMedline
  • 29 Bergsma DJ, Ellis C, Kumar C, et al. Cloning and characterization of a human angiotensin II type 1 receptor. Biochem Biophys Res Commun.1992;183:989–995.CrossrefMedline
  • 30 Kambayashi Y, Bardhan S, Takahashi K, et al. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem.1993;268:24543–24546.Medline
  • 31 Mukoyama M, Nakajima M, Horiuchi M, et al. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem.1993;68:24539–24542.
  • 32 Ohkubo N, Matsubara H, Nozawa Y, et al. Angiotensin type 2 receptors are re-expressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation.1997;96:3954–3962.CrossrefMedline
  • 33 Janiak P, Pillon A, Prost JF, et al. Role of angiotensin subtype 2 receptor in neointima formation after vascular injury. Hypertension.1992;20:737–745.
  • 34 Nio Y, Matsubara H, Murasawa S, et al. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest.1995;95:46–54.CrossrefMedline
  • 35 Sugaya T, Nishimatsu S, Tanimoto K, et al. Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J Biol Chem.1995;270:18719–18722.CrossrefMedline
  • 36 Harada K, Sugaya T, Murakami K, et al. Angiotensin II type 1a receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation.1999;100:2093–2099.CrossrefMedline
  • 37 Nakajima M, Hutchinson HG, Fujinaga M, et al. The angiotensin II type 2 (AT2) receptor antagonizes the growth effect of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci U S A.1995;92:10663–10667.CrossrefMedline
  • 38 Stoll M, Steckelings M, Paul M, et al. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest.1995;95:651–657.CrossrefMedline
  • 39 Meffert S, Stoll M, Steckelings UM, et al. The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells. Mol Cell Endocrinol.1996;122:59–67.CrossrefMedline
  • 40 Morrissey JJ, Klahr S. Effect of AT2 receptor blockade on the pathogenesis of renal fibrosis. Am J Physiol. 1999;276(1 pt 2):F39–F45.
  • 41 Li JS, Touyz RM, Schiffrin EL. Effects of AT1 and AT2 angiotensin receptor antagonists in angiotensin II-infused rats. Hypertension.1998;31:487–492.CrossrefMedline
  • 42 Cao Z, Dean R, Wu L, et al. Role of angiotensin receptor subtypes in mesenteric vascular proliferation and hypertrophy. Hypertension.1999;34:408–414.CrossrefMedline
  • 43 Siragy HM, Carey RM. The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3′, 5′-monophosphate and AT1 receptor -mediated prostaglandin E2 production in conscious rats. J Clin Invest.1996;97:1978–1982.CrossrefMedline
  • 44 Wexler RR, Greenlee WJ, Irvin JD, et al. Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. J Med Chem.1996;39:625–656.CrossrefMedline
  • 45 Fierens F, Vanderheyden PML, De Backer JP, et al. Binding of the antagonist [3H] candesartan to angiotensin II AT1 receptor-transfected Chinese hamster ovary cells. Eur J Pharmacol.1999;367:413–422.CrossrefMedline
  • 46 Fierens FLP, Vanderheyden PML, De Backer JP, et al. Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding. Eur J Pharmacol.1999;372:199–206.CrossrefMedline
  • 47 Christen Y, Waeber B, Nussberger J, et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. Circulation.1991;83:1333–1342.CrossrefMedline
  • 48 Munafo H, Christen Y, Nussberger J, et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther.1992;51:513–521.CrossrefMedline
  • 49 Muller P, Cohen T, De Gasparo M, et al. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol.1994;47:231–245.CrossrefMedline
  • 50 Delacretaz E, Nussberger J, Biollaz J, et al. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension.1995;25:14–21.CrossrefMedline
  • 51 Reeves RA, Lin CS, Kassler-Taub K, et al. Dose-related efficacy of irbesartan for hypertension: an integrated analysis. Hypertension.1998;31:1311–1316.CrossrefMedline
  • 52 Bottorf MB, Tenero DM. Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations. Phamacotherapy. 1999;19(4 pt 2):73S–78S.
  • 53 Tikkanen I, Omvik P, Jensen HA, et al. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens.1995;13:1343–1351.CrossrefMedline
  • 54 Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension.1995;25:1345–1350.CrossrefMedline
  • 55 Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol.1995;75:793–795.CrossrefMedline
  • 56 Weber MA, Byyny RL, Pratt JH, et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med.1995;155:405–411.CrossrefMedline
  • 57 Dahlöf B, Keller S, Makris L, et al. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens.1995;8:578–583.CrossrefMedline
  • 58 Weir MR, Elkins M, Liss C, et al. Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. Clin Ther.1996;18:411–428.CrossrefMedline
  • 59 MacKay JH, Arcuti KE, Goldberg AI, et al. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. Arch Intern Med.1996;156:278–279.CrossrefMedline
  • 60 Ruff D, Gazdick LP, Berman R, et al. Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension. J Hypertens.1996;14:263–270.CrossrefMedline
  • 61 Oparil S, Dyke S, Harris F, et al. The efficacy and safety of valsartan compared with placebo in the treatment of essential hypertension. Clin Ther.1996;18:797–810.CrossrefMedline
  • 62 Neutel J, Weber M, Pool J, et al. Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours. Clin Ther.1997;19:447–458.CrossrefMedline
  • 63 Corea L, Cardoni O, Fogari R, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther.1996;60:341–346.CrossrefMedline
  • 64 Holwerda N, Fogari R, Angeli P, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens.1996;14:1147–1151.CrossrefMedline
  • 65 Black HR, Graff A, Shute R, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens.1997;11:483–489.CrossrefMedline
  • 66 Hegner G, Faust G, Freytag F, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide. Eur J Clin Pharmacol.1997;52:173–177.CrossrefMedline
  • 67 Bremner AD, Baur M, Oddou-Stock P, et al. Valsartan: long term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension. Clin Exp Hypertens.1997;19:1263–1285.CrossrefMedline
  • 68 Cifkova R, Peleska J, Hradec J, et al. Valsartan and atenolol in patients with severe primary hypertension. J Hum Hypertens.1998;12:563–567.CrossrefMedline
  • 69 Fogari R, Ambrosoli S, Corradi L, et al. 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring: Irbesartan Multicenter Investigators’ Group. J Hypertens.1997;15:1511–1518.CrossrefMedline
  • 70 Pool JL, Guthrie RM, Littlejohn TW, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens.1998;11:462–470.CrossrefMedline
  • 71 Larochelle P, Flack JM, Marbury TC, et al. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension: Irbesartan Multicenter Investigators. Am J Cardiol.1997;80:1613–1615.CrossrefMedline
  • 72 Mimran A, Ruilope L, Kerwin L, et al. A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens.1998;12:203–208.CrossrefMedline
  • 73 Stumpe KO, Haworth D, Hoglund C, et al. Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension. Blood Press.1998;7:31–37.CrossrefMedline
  • 74 Elmfeldt D, George M, Hubner R, et al. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens.1997;11:S49–S53.Medline
  • 75 Zanchetti A, Omboni S, DiBaggio C, on behalf of the Study Group. Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension. J Hum Hypertens. 1997;11(suppl 2):S57–S59.
  • 76 Plouin PF. Combination therapy with candesartan cilexetil hydrochlorothiazide in patients unresponsive to low-dose hydrochlorothiazide. J Hum Hypertens. 1997;11(suppl 2):S65–S66,.
  • 77 Smith DHG, Neutel JM, Morgenstern P. Once-daily telmisartan compared with enalapril in the treatment of hypertension. Adv Ther.1998;15:229–240.
  • 78 Neutel JM, Smith DHG, Reilly PA. The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension. Int J Clin Pract. 1999;53(3):1–4.
  • 79 Neutel JM, Smith DHG. Dose response and antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther.1998;15:206–217.
  • 80 Weber M. Clinical efficacy of eprosartan. Phamacotherapy. 1999;19(4 pt 2):95S–101S.
  • 81 Mazzolai L, Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Safety.1999;21:23–33.CrossrefMedline
  • 82 Lacourcière Y, Brunner HR, Irwin R, et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens.1994;12:1387–1393.Medline
  • 83 Benz J, Oshrain C, Henry D, et al. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol.1997;37:101–107.CrossrefMedline
  • 84 Lacourcière Y. The incidence of cough: a comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist. Int J Clin Pract.1999;53:99–103.Medline
  • 85 Van Rijnsoever EW, Kwee-Zuiderwijk WJ, Feenstra J. Angioneurotic edema attributed to the use of losartan. Arch Intern Med.1998;158:2063–2065.CrossrefMedline
  • 86 Julian BA, Brantley RR Jr, Barker CV, et al. Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. J Am Soc Nephrol.1998;9:1104–1108.Medline
  • 87 Hortal L, Fernandez A, Vega N, et al. Losartan versus ramipril in the treatment of postrenal transplant erythrocytosis. Transplant Proc.1998;30:2127–2128.CrossrefMedline
  • 88 Nakashima M, Uematsu T, Kosuge K, et al. Pilot study of the uricosuric effect of DuP 753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol.1992;42:333–335.CrossrefMedline
  • 89 Burnier M, Rutschmann B, Nussberger J, et al. Salt-dependent renal effects of angiotensin II antagonist in healthy subjects. Hypertension.1993;22:339–347.
  • 90 Burnier M, Roch-Ramel F, Brunner HR. Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int.1996;49:1787–1790.CrossrefMedline
  • 91 Pitt B, Segal R, Martinez FA, Meurers G, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan In The Elderly study, ELITE). Lancet.1997;349:747–752.CrossrefMedline
  • 92 Burnier M, Hagman M, Nussberger J, et al. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension.1995;25:602–609.CrossrefMedline
  • 93 Gansevoort RT, DeZeeuw D, deJong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int.1994;45:861–867.CrossrefMedline
  • 94 Pechère-Bertschi A, Nussberger J, Decosterd L, et al. Renal response to the AT1 antagonist irbesartan vs enalapril in hypertensive patients. J Hypertens.1998;16:385–393.CrossrefMedline
  • 95 Remuzzi A, Perico N, Sangalli F, et al. ACE inhibition and AngII receptor blockade improve glomerular size-selectivity in IgA nephropathy. Am J Physiol.1999;276:F457–F466.Medline
  • 96 Plum J, Buenten B, Nemeth R, et al. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. J Am Soc Nephrol.1998;9:2223–2234.Medline
  • 97 Perico N, Remuzzi A, Sangalli F, et al. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. J Am Soc Nephrol.1998;9:2308–2317.Medline
  • 98 Lafayette RA, Mayer G, Park SK, et al. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest.1992;90:766–771.CrossrefMedline
  • 99 Remuzzi A, Fassi A, Sangalli F, et al. Prevention of renal injury in diabetic MWF rats by angiotensin II antagonism. Exp Nephrol.1998;6:28–38.CrossrefMedline
  • 100 Thuermann PA, Kenedi P, Schmidt A, et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation.1998;98:2037–2042.CrossrefMedline
  • 101 Gottlieb SS, Dickstein K, Fleck E, et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation. 1993;88(part 1):1602–1609.
  • 102 Dickstein K, Chang P, Willenheimer R, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe heart failure. J Am Coll Cardiol.1995;26:438–445.CrossrefMedline
  • 103 Crozier I, Ikram H, Awan N, et al. Losartan in heart failure: hemodynamic effects and tolerability. Circulation.1995;91:691–697.CrossrefMedline
  • 104 Havranek EP, Thomas I, Smith WB, et al. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. J Am Coll Cardiol.1999;33:1174–1181.CrossrefMedline
  • 105 Baruch L, Anand I, Cohen IS, et al. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to an angiotensin converting enzyme inhibitor therapy in patients with heart failure: Vasodilator Heart Failure Trial (V-HeFT) study group. Circulation.1999;99:2658–2664.CrossrefMedline
  • 106 Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial: the Losartan Heart Failure Survival Study ELITE II. Lancet.2000;255:1582–1587.
  • 107 Mazzolai L, Maillard M, Rossat J, et al. Angiotensin II receptor blockade in normal subjects: a direct comparison of three AT1 receptor antagonists. Hypertension.1999;33:850–855.CrossrefMedline
  • 108 Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens.2000;13:418–426.
  • 109 Hedner T, Oparil S, Rasmussen K, et al. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens.1999;12:414–417.CrossrefMedline
  • 110 Fogari R, Zoppi A, Mugellini A, et al. Comparative efficacy of losartan and valsartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring. Current Ther Res.1999;60:195–206.Crossref
  • 111 Andeon OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press.1998;7:53–59.CrossrefMedline
  • 112 Kassler-Taub K, Littlejohn T, Elliott W, et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens.1998;11:445–453.CrossrefMedline
  • 113 Oparil S, Guthrie R, Lewin AJ, et al. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers irbesartan and losartan. Clin Ther.1998;20:398–409.CrossrefMedline
  • 114 Mallion JM, Siche JP, Lacourcière Y, and the Telmisartan Blood Pressure Monitoring Group. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens.1999;13:657–664.CrossrefMedline
  • 115 Willenheimer R, Dahlöf B, Rydberg E, et al. AT1 receptor blockers in hypertension and heart failure: clinical experience and future directions. Eur Heart J.1999;20:997–1008.CrossrefMedline
  • 116 Azizi M, Chatellier G, Guyene TT, et al. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation.1995;92:825–834.CrossrefMedline
  • 117 Ots M, MacKenzie HS, Troy JL, et al. Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol.1998;9:224–230.Medline
  • 118 Hebert LA, Falkenheim ME, Nahman NS, et al. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol.1999;19:1–6.CrossrefMedline
  • 119 Russo D, Pisani A, Balletta MM, et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis.1999;33:851–856.CrossrefMedline
  • 120 McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation.1999;100:1056–1064.CrossrefMedline
  • 121 Hamroff G, Katz SD, Mancini D, et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation.1999;99:990–992.CrossrefMedline
apothekegenerika.com/

www.pharmacy24.com.ua

www.cialis-viagra.com.ua